PROCEPT BioRobotics Q3 2025 Earnings Report

PROCEPT BioRobotics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.41
• Beat/Miss: N/A
• One Year Ago EPS: N/A

PROCEPT BioRobotics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $80.78 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

PROCEPT BioRobotics Announcement Details

• Quarter: Q3 2025
• Date: 10/27/2025
• Time: Before Market Opens
• Conference Call Date: Monday, October 27, 2025
• Conference Call Time: 8:00AM ET

PROCEPT BioRobotics (NASDAQ:PRCT), Inc. is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures. The system is designed for use in an outpatient setting, offering physicians a controlled robotic platform to carry out targeted tissue resection without the need for thermal energy. This approach is intended to minimize complications such as urinary incontinence and sexual dysfunction often associated with conventional BPH treatments.

Headquartered in Redwood City, California, PROCEPT BioRobotics was founded in 2008 by Serdar Bozkurt, MD, who continues to serve as Chief Medical Officer. The AquaBeam Robotic System received U.S. Food and Drug Administration (FDA) clearance in 2016 and a CE mark for European markets, positioning the company to serve healthcare providers across North America and select international territories. PROCEPT has built a network of clinical partners and distributors to support physician training and system installation.

With a focus on advancing urological care through innovation, PROCEPT BioRobotics invests in ongoing research and development to expand its platform’s capabilities and explore new indications. The company maintains collaborations with leading academic institutions and surgical centers to refine procedural protocols and gather long-term clinical data, underscoring its commitment to evidence-based adoption of robotic waterjet ablation technology.